Bachem Announces Progress in Building K Start-Up and Expansion of Its Site in Vista, CA
Bubendorf, Switzerland--(Newsfile Corp. - October 23, 202
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-10-23 1:01 AM EDT | Bachem Holding AG
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce that the Government of Japan has
Biotechnology, Pharmaceuticals, Health
2025-10-22 10:04 AM EDT | Hemostemix Inc.
OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. - October 22, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced additional overall and event free survival data generated from the Company's 41-patient Phase 2b clinical trial of its off-the-shelf immunotherapeutic candidate OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma (the "Phase 2b Ost
2025-10-22 9:15 AM EDT | OS Therapies
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-21 7:45 AM EDT | Phio Pharmaceuticals Corp.
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025. Next-generation therapy CR
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-10-21 7:27 AM EDT | Cardiol Therapeutics Inc.
Optimi Health Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian manufacturer of pharmaceutical psychedelics including MDMA and naturally-derived psilocybin, is pleased to announce that it has passed its Drug Establishment Licence (DEL) inspection by Health Canada, with no critical observations, resulting in a GMP-compliant rating for the fabrication and distribution of phar
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-10-21 7:00 AM EDT | Optimi Health Corp.
TempraMed Announces Private Placement of up to C$2.5 Million
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce a non-brokered private placement (the "Offering") of up to 3,289,473 units of the Company (each, a "Unit") at a price of C$0.76 per Unit for aggregate gross proceeds of up to C$2,500,000. Each Unit will consist of one common share of the Company (each, a "Share") and one Share purcha
Technology, Biotechnology, Pharmaceuticals, Health
2025-10-21 7:00 AM EDT | TempraMed Technologies Ltd
Adaptimmune Announces Delisting from Nasdaq
Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determined to initiate the delisting of its American Depositary Shares ("ADSs"), each representing six ordinary shares, from The Nasdaq Capital Market ("Nasdaq") and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (th
Biotechnology, Healthcare and Hospitals
2025-10-20 7:40 AM EDT | Adaptimmune Therapeutics PLC
PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that, further to its News Releases of September 4, 2025, September 19, 2025 and October 10, 2025, it will be proceeding to complete its previou
Biotechnology, Pharmaceuticals, Health
2025-10-20 7:00 AM EDT | PreveCeutical Medical Inc.
Sona Nanotech Reports 80% Response Rate in First-In-Human THT Cancer Therapy Study
Halifax, Nova Scotia--(Newsfile Corp. - October 20, 2025) - Sona Nanotech Inc., (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), is pleased to announce the completion of its first-in-human clinical study treating patients with histologically confirmed, immunotherapy-resistant cutaneous metastatic melanoma using Sona's Targeted Hyperthermia Therapy ("THT"). Ten advanced-stage patients, all of whom were failing to respond to standard immunotherapy treatment, were recruited int
2025-10-20 6:00 AM EDT | Sona Nanotech Inc.
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025. Next-generation therapy CR
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-10-17 4:34 PM EDT | Cardiol Therapeutics Inc.
Sona Nanotech To Host Investor Webinar To Discuss Clinical Study
Halifax, Nova Scotia--(Newsfile Corp. - October 17, 2025) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona"), announces that it will host a webinar on Monday, October 20th at noon EDT to discuss its first-in-human, early feasibility clinical study for its Targeted Hyperthermia Therapy cancer treatment. Ten advanced stage melanoma patients who were failing to respond to standard immunotherapy treatment were recruited into this early feasibility stu
2025-10-17 4:04 PM EDT | Sona Nanotech Inc.
OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. - October 17, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug co
2025-10-17 9:15 AM EDT | OS Therapies
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today applauds the U.S. Food and Drug Administration's ("FDA") announcement on October 16, 2025 of the first-ever recipients of the new Commissioner's National Priority Voucher ("CNPV") pilot program, which include "ketamine for domestic manufacturing of a
Biotechnology, Pharmaceuticals
2025-10-17 8:26 AM EDT | PharmaTher Holdings Ltd.
InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 16, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors, effective immediately. Mr. Bathery brings more than 30 years of experience in the pharmaceutical industry, including over 15 yea
Biotechnology, Pharmaceuticals
2025-10-16 8:30 AM EDT | InMed Pharmaceuticals
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
Toronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced that it has begun preparing its U.S. Food and Drug Administration ("FDA") briefing materials to discuss a Phase 3 program for ketamine in levodopa-induced dyskinesia in Parkinson's disease ("LID-PD") and that prospective pharma partn
Biotechnology, Pharmaceuticals
2025-10-16 8:00 AM EDT | PharmaTher Holdings Ltd.
Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol
Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, in Florida under Florida's SB 1768, is pleased to annou
Biotechnology, Pharmaceuticals, Health
2025-10-15 3:51 PM EDT | Hemostemix Inc.
Marc Walther, President and CEO of Impact Fusion Files a Patent Pending Related to Artificial Insemination of Mammals
Napoleonville, Louisiana--(Newsfile Corp. - October 15, 2025) - Impact Fusion (OTCID: IFUS) announced today, that Marc Walther, President and CEO filed a Patent Pending on Thursday October 9, 2025 with the USPO related to the artificial insemination of mammals. Impact Fusion Artificial Insemination Technology™ (Impact Fusion AIT™) is available now. "I have long been aware of the importance of dairymen and cattle ranchers being able to have access to reliable, cos
2025-10-15 1:15 PM EDT | Impact Fusion International Inc.
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life sciences company focused on unlocking the pharmaceutical potential of ketamine, today announced KetAImine™, a proprietary ketamine repurposing and discovery platform designed to create, prioritize, and de-risk new ketamine indications and combination therapies across therapeutic areas—forming a scalable pipeline for
Biotechnology, Pharmaceuticals
2025-10-15 8:00 AM EDT | PharmaTher Holdings Ltd.
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025
Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Growth Summit in New York and give an overview of its development pipeline at Eyecelerator @ AAO 2025 in Orlando. Maxim Growth Summit Ophthalmology Panel Details Title: A vision of innovation; Advances in biotechnology have spurred innovation in the manageme
Biotechnology, Pharmaceuticals
2025-10-15 7:00 AM EDT | Kiora Pharmaceuticals, Inc.